Biomarin Pharmaceutical Inc (BMRN) - Total Liabilities
Based on the latest financial reports, Biomarin Pharmaceutical Inc (BMRN) has total liabilities worth $2.38 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biomarin Pharmaceutical Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's total liabilities have evolved over time, based on quarterly financial data. See BMRN net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Biomarin Pharmaceutical Inc Competitors by Total Liabilities
The table below lists competitors of Biomarin Pharmaceutical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SEI Investments Company
NASDAQ:SEIC
|
USA | $518.57 Million |
|
Guangxi Guiguan Electric Power Co Ltd
SHG:600236
|
China | CN¥30.19 Billion |
|
Focus Media Information Technology Co Ltd
SHE:002027
|
China | CN¥6.96 Billion |
|
China Railway Construction Corp Ltd
SHG:601186
|
China | CN¥1.70 Trillion |
|
Suzano S.A.
SA:SUZB3
|
Brazil | R$117.64 Billion |
|
Pentair plc
F:PNT
|
Germany | €3.26 Billion |
|
China Communications Construction Co Ltd
SHG:601800
|
China | CN¥1.59 Trillion |
|
RAKUTEN GROUP SPONS.ADR 1
F:RAKA
|
Germany | €27.45 Trillion |
Liability Composition Analysis (1998–2025)
This chart breaks down Biomarin Pharmaceutical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biomarin Pharmaceutical Inc (BMRN) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomarin Pharmaceutical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomarin Pharmaceutical Inc (1998–2025)
The table below shows the annual total liabilities of Biomarin Pharmaceutical Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.51 Billion | +13.23% |
| 2024-12-31 | $1.33 Billion | -29.58% |
| 2023-12-31 | $1.89 Billion | +6.67% |
| 2022-12-31 | $1.77 Billion | +2.27% |
| 2021-12-31 | $1.73 Billion | -0.54% |
| 2020-12-31 | $1.74 Billion | +11.12% |
| 2019-12-31 | $1.57 Billion | +7.43% |
| 2018-12-31 | $1.46 Billion | -20.02% |
| 2017-12-31 | $1.82 Billion | +45.10% |
| 2016-12-31 | $1.26 Billion | -5.35% |
| 2015-12-31 | $1.33 Billion | +38.02% |
| 2014-12-31 | $962.56 Million | +6.59% |
| 2013-12-31 | $903.02 Million | +63.42% |
| 2012-12-31 | $552.58 Million | +3.74% |
| 2011-12-31 | $532.66 Million | -2.33% |
| 2010-12-31 | $545.37 Million | -8.34% |
| 2009-12-31 | $594.98 Million | -5.56% |
| 2008-12-31 | $630.02 Million | +0.39% |
| 2007-12-31 | $627.55 Million | +81.57% |
| 2006-12-31 | $345.63 Million | +26.71% |
| 2005-12-31 | $272.76 Million | -9.36% |
| 2004-12-31 | $300.94 Million | +117.31% |
| 2003-12-31 | $138.49 Million | +1047.08% |
| 2002-12-31 | $12.07 Million | -1.55% |
| 2001-12-31 | $12.26 Million | +76.73% |
| 2000-12-31 | $6.94 Million | +34.16% |
| 1999-12-31 | $5.17 Million | +145.12% |
| 1998-12-31 | $2.11 Million | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more